Literature DB >> 11061653

Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children.

D Jaquet1, M Lévine, E Ortega-Rodriguez, A Faye, M Polak, E Vilmer, C Lévy-Marchal.   

Abstract

OBJECTIVE: To investigate body fat distribution and glucose and lipid metabolism in HIV-infected children with the aim of describing the lipodystrophic syndrome in children.
DESIGN: Cross-sectional study including 39 HIV-infected children aged 3-18 years. MAIN OUTCOME MEASURES: Clinical lipodystrophy was defined as peripheral fat wasting (facial and/or buttock and/or limb atrophy with arm skinfold thickness lower than the third percentile of the reference values for sex and age) and/or truncal adiposity (breast enlargement and/or buffalo neck and/or relative abdominal obesity with trunk : arm skinfold ratio > 2 standard deviations). Fasting serum lipid concentrations were measured and an oral glucose tolerance test was performed.
RESULTS: Of 39 HIV-infected children, lipodystrophy was observed in 13 children (33.3%): eight with truncal lipohypertrophy, three with peripheral lipoatrophy and two with combined lipodystrophy. Combined lipodystrophies were observed only in adolescents with a more severe presentation than in prepubertal children. Lipodystrophic children had higher fasting insulinaemia (7.0+/-8.5 versus 3.0+/-2.3 microU/ml; P = 0.07), suggesting a certain degree of insulin-resistance. Hypercholesterolaemia (23% versus 15%; P = 0.59 ) and hypertriglyceridaemia (15% versus 11%; P = 0.76) were observed with the same proportion in the lipodystrophic as in the non-lipodystrophic groups; 23% of the non-lipodystrophic children had dyslipidaemia.
CONCLUSION: The lipodystrophic syndrome prevails in HIV-infected children in the three clinical forms initially described in adults but appears less severe before the initiation of puberty. Insulin-resistance occurs in lipodystrophic children only, whereas dyslipidaemia exists in non-lipodystrophic children as well, suggesting that dyslipidaemia could reflect subclinical alteration of the adipose tissue.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061653     DOI: 10.1097/00002030-200009290-00008

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  35 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Longevity on Antiretroviral Therapy for Children Living with HIV/AIDS--A Price to Pay for Success?

Authors:  Mamatha M Lala; Rashid H Merchant
Journal:  Indian J Pediatr       Date:  2016-02-06       Impact factor: 1.967

3.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

4.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

Review 5.  Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Authors:  Roy J Kim; Richard M Rutstein
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

6.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Authors:  Ana María Sánchez Torres; Raquel Munoz Muniz; Rosario Madero; Clementina Borque; María Jesús García-Miguel; María Isabel De José Gómez
Journal:  Eur J Pediatr       Date:  2005-01-14       Impact factor: 3.183

Review 7.  Management of antiretroviral therapy in neonates, children, and adolescents.

Authors:  Michael Neely; Andrea Kovacs
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

8.  Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.

Authors:  Stephen Arpadi; Stephanie Shiau; Renate Strehlau; Leigh Martens; Faeezah Patel; Ashraf Coovadia; Elaine J Abrams; Louise Kuhn
Journal:  Arch Dis Child       Date:  2012-12-05       Impact factor: 3.791

Review 9.  The role of protease inhibitor therapy in children with HIV infection.

Authors:  Patrick J Gavin; Ram Yogev
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 10.  Addressing malnutrition in young children in South Africa. Setting the national context for paediatric food-based dietary guidelines.

Authors:  Lesley T Bourne; Michael K Hendricks; Debbie Marais; Brian Eley
Journal:  Matern Child Nutr       Date:  2007-10       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.